The role of novel anticoagulants in the management of venous thromboembolism.
Venous thromboembolism (VTE) is a common health condition with a high mortality and morbidity as well as significant health cost. Traditional treatment with parenteral heparin followed by vitamin K antagonist (VKA) has helped to decrease both morbidity and mortality over years. However, difficulties with warfarin such as INR monitoring, drug-drug interactions, and dietary restrictions has led to research for new anticoagulants. Thus, novel anticoagulants such as direct thrombin and factor X inhibitors have been developed and studied for various indications including the management of VTE. There is now good evidence that some novel anticoagulants are at least as effective as traditional anticoagulation therapy with probably safer outcomes. We have reviewed the literature on the medical management of VTE with the focus on the role of dabigatran, rivaroxaban, apixaban and edoxaban for this indication.